Travere Therapeutics Inc (TVTX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.86B
Last updated: Nov 17, 2026 at 11:06 AM ET
Travere Therapeutics Inc (TVTX) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Travere Therapeutics reported EPS of -$0.55, below the -$0.25 estimate. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
Analysts' consensus for the quarter ending Dec 31, 2026 is 29.7% above the $0.37 reported for the quarter ended Dec 31, 2025.
TVTX's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
TVTX Earnings Call
The latest TVTX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 38 quarters below that had an estimate, TVTX beat 21, missed 16 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $224.56M, up 36.2% from $164.86M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.55 | -$0.25 | -$0.57 - $0.71 | -120.00% | Miss | -193.2% | 8 | 2 up, 0 down | Nov 2, 2026 | $224.56M |
| Jun 30, 2026 | -$0.37 | -$0.14 | N/A | -164.29% | Miss | -384.6% | 8 | 2 up, 0 down | Aug 4, 2026 | $169.58M |
| Mar 31, 2026 | $0.05 | -$0.06 | -$0.25 - $0.18 | +183.33% | Beat | N/A | 6 | 0 up, 1 down | May 4, 2026 | $127.20M |
| Dec 31, 2025 | $0.37 | -$0.04 | N/A | N/A | N/A | N/A | 7 | 3 up, 0 down | Feb 19, 2026 | $129.69M |
| Sep 30, 2025 | $0.59 | -$0.08 | -$0.25 - $0.01 | +837.50% | Beat | N/A | 8 | 4 up, 2 down | Oct 30, 2025 | $164.86M |
| Jun 30, 2025 | $0.13 | $0.04 | -$0.15 - $0.14 | +225.00% | Beat | N/A | 8 | 1 up, 1 down | Aug 6, 2025 | $114.45M |
| Mar 31, 2025 | -$0.19 | -$0.39 | -$0.51 - -$0.27 | +51.28% | Beat | N/A | 7 | 0 up, 4 down | May 1, 2025 | $81.73M |
| Dec 31, 2024 | -$0.47 | -$0.38 | -$0.52 - -$0.28 | -24.14% | Miss | N/A | 7 | 3 up, 0 down | Feb 20, 2025 | $74.79M |
| Sep 30, 2024 | -$0.46 | -$0.54 | -$0.97 - -$0.50 | +14.81% | Beat | -120.3% | 10 | 5 up, 1 down | Oct 31, 2024 | $62.90M |
| Jun 30, 2024 | -$0.65 | -$0.72 | -$1.06 - -$0.64 | +9.72% | Beat | N/A | 10 | 0 up, 0 down | Aug 1, 2024 | $54.12M |
| Mar 31, 2024 | -$1.51 | -$0.79 | -$1.27 - -$0.78 | -91.14% | Miss | N/A | 11 | 0 up, 1 down | May 6, 2024 | $41.37M |
| Dec 31, 2023 | -$0.94 | -$0.92 | -$1.57 - -$0.85 | -2.17% | Miss | N/A | 12 | 3 up, 0 down | Feb 15, 2024 | $45.06M |
| Sep 30, 2023 | $2.27 | $0.04 | -$1.35 - $1.67 | N/A | N/A | N/A | 11 | 2 up, 0 down | Nov 7, 2023 | $37.09M |
| Jun 30, 2023 | -$0.77 | -$0.93 | -$1.30 - -$0.93 | +17.20% | Beat | N/A | 11 | 1 up, 1 down | Aug 3, 2023 | $32.20M |
| Mar 31, 2023 | -$0.82 | -$1.03 | -$1.49 - -$0.77 | +20.39% | Beat | N/A | 9 | 2 up, 0 down | May 4, 2023 | $56.99M |
| Dec 31, 2022 | -$1.03 | -$1.07 | -$1.35 - -$0.88 | +3.74% | Beat | N/A | 9 | 1 up, 2 down | Feb 23, 2023 | $55.87M |
| Sep 30, 2022 | -$0.76 | -$0.70 | -$1.11 - -$0.63 | -8.57% | Miss | N/A | 7 | 2 up, 0 down | Oct 27, 2022 | $28.07M |
| Jun 30, 2022 | -$0.65 | -$0.70 | -$1.01 - -$0.51 | +7.14% | Beat | N/A | 8 | 0 up, 1 down | Aug 4, 2022 | $54.17M |
| Mar 31, 2022 | -$0.82 | -$0.73 | -$1.03 - -$0.63 | -12.33% | Miss | N/A | 7 | 0 up, 1 down | May 5, 2022 | $48.49M |
| Dec 31, 2021 | -$0.61 | -$0.50 | -$1.14 - -$0.33 | -22.00% | Miss | N/A | 6 | 1 up, 0 down | Feb 24, 2022 | $57.25M |
| Sep 30, 2021 | -$0.13 | -$0.48 | N/A | +72.92% | Beat | N/A | 4 | 1 up, 0 down | Oct 28, 2021 | $68.22M |
| Jun 30, 2021 | -$0.39 | -$0.50 | N/A | +22.00% | Beat | N/A | 6 | N/A | Jul 29, 2021 | $54.62M |
| Mar 31, 2021 | -$0.55 | -$0.30 | -$0.68 - -$0.22 | -83.33% | Miss | N/A | 7 | N/A | May 6, 2021 | $47.41M |
| Dec 31, 2020 | -$0.48 | -$0.47 | -$0.71 - -$0.28 | -2.13% | Miss | N/A | 8 | N/A | Mar 1, 2021 | $50.98M |
| Sep 30, 2020 | -$0.11 | -$0.29 | N/A | +62.07% | Beat | N/A | N/A | N/A | Nov 5, 2020 | $51.14M |
| Jun 30, 2020 | -$0.22 | -$0.36 | N/A | +38.89% | Beat | N/A | N/A | N/A | Jul 30, 2020 | $48.43M |
| Mar 31, 2020 | -$0.20 | -$0.52 | N/A | +61.54% | Beat | N/A | N/A | N/A | May 11, 2020 | $47.77M |
| Dec 31, 2019 | -$0.26 | -$0.37 | N/A | +29.73% | Beat | N/A | N/A | N/A | Feb 24, 2020 | $46.69M |
| Sep 30, 2019 | -$0.66 | -$0.60 | N/A | -10.00% | Miss | N/A | N/A | N/A | Oct 30, 2019 | $44.37M |
| Jun 30, 2019 | -$0.58 | -$0.40 | N/A | -45.00% | Miss | N/A | N/A | N/A | Aug 6, 2019 | $44.71M |
| Mar 31, 2019 | -$0.63 | -$0.36 | N/A | -75.00% | Miss | N/A | N/A | N/A | May 7, 2019 | $39.57M |
| Dec 31, 2018 | -$0.18 | -$0.48 | N/A | +62.50% | Beat | N/A | N/A | N/A | Feb 26, 2019 | $43.77M |
| Sep 30, 2018 | -$0.68 | -$0.26 | N/A | -161.54% | Miss | -553.3% | N/A | N/A | Nov 1, 2018 | $40.71M |
| Jun 30, 2018 | -$0.25 | -$0.11 | N/A | -127.27% | Miss | -933.3% | N/A | N/A | Jul 26, 2018 | $41.34M |
| Mar 31, 2018 | -$0.14 | -$0.36 | N/A | +61.11% | Beat | -1500.0% | N/A | N/A | May 1, 2018 | $38.43M |
| Dec 31, 2017 | -$0.45 | -$0.19 | N/A | -136.84% | Miss | N/A | N/A | N/A | Feb 27, 2018 | $42.18M |
| Sep 30, 2017 | $0.15 | -$0.04 | N/A | +475.00% | Beat | N/A | N/A | N/A | Nov 7, 2017 | $40.34M |
| Jun 30, 2017 | $0.03 | $0.03 | N/A | 0.00% | In line | -57.1% | N/A | N/A | Aug 9, 2017 | $38.80M |
| Mar 31, 2017 | $0.01 | -$0.26 | N/A | +103.85% | Beat | -92.9% | N/A | N/A | May 4, 2017 | $33.62M |
| Dec 31, 2016 | -$0.23 | -$0.26 | N/A | +11.54% | Beat | N/A | N/A | N/A | Mar 1, 2017 | $37.33M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.90, a profit after a loss of $3.09 per share the year before. It was -$0.11 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.90 | N/A |
| Dec 31, 2024 | -$3.09 | N/A |
| Dec 31, 2023 | -$0.26 | N/A |
| Dec 31, 2022 | -$3.26 | N/A |
| Dec 31, 2021 | -$1.68 | N/A |
| Dec 31, 2020 | -$1.01 | N/A |
| Dec 31, 2019 | -$2.13 | N/A |
| Dec 31, 2018 | -$1.25 | N/A |
| Dec 31, 2017 | -$0.26 | N/A |
| Dec 31, 2016 | -$0.11 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,400 words across 18 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,367 | 18 | |
| 2026Q2 | Jun 30, 2026 | 6,942 | 19 | |
| 2026Q1 | Mar 31, 2026 | 6,829 | 19 | |
| 2025Q4 | Dec 31, 2025 | 7,462 | 19 | |
| 2025Q3 | Sep 30, 2025 | 6,667 | 19 | |
| 2025Q2 | Jun 30, 2025 | 6,456 | 19 | |
| 2025Q1 | Mar 31, 2025 | 7,175 | 17 | |
| 2024Q4 | Dec 31, 2024 | 8,658 | 19 |
2026Q3 Earnings Call
Opening remarks
Nivi Nehra Investor Relations Thank you, operator. Good afternoon, and welcome to Travere Therapeutics' Third Quarter 2026 Financial Results and Corporate Update Call. Thank you all for joining. Today's call will be led by Dr. Eric Dube, our president and chief executive officer. Eric will be joined in the prepared remarks by Peter Heerma, our chief commercial officer; Dr. Jula Inrig, our head of R&D and chief medical officer; and Christopher Cline, our chief financial officer. William E. Rote, our chief research officer, will join us for the Q&A. Before we begin, I would like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 2000. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties, and assumptions that may cause actual results, performance, and achievements to differ materially from those expressed or implied by the statements. Please see the forward-looking statement disclaimer on the company's press release issued earlier today, as well as the risk factors section in our Forms 10-Q and 10-K filed with the SEC. In addition, any forward-looking statements represent our views only as of the date such statements are made, November 2, 2026. Travere specifically disclaims any obligation to update such statements to reflect future information, events, or circumstances. With that, let me now turn the call over to Eric.
Eric Dube President and Chief Executive Officer Good afternoon. Thank you for joining us today as we discuss another quarter of excellent execution and continued momentum across Travere's commercial business and pipeline. Before turning to our results, I would like to briefly reflect on my upcoming transition that was announced during the quarter. As I prepare to step down in December, I have been reflecting on the people and purpose that have shaped my time at Travere. Being part of this company has been the greatest privilege of my career, and I am deeply proud of what we have accomplished. I have never been more confident that Travere's best days are ahead, with an exceptional executive team, life-changing therapies, a growing pipeline, and an organization committed to delivering for patients. I have been in regular communication with Bradley as we plan for him joining Travere on December 1. This time together has only strengthened my conviction that he is the perfect fit to lead Travere into its next chapter. He shares our commitment to patients and brings the experience, perspective, and leadership to build on our momentum. We are approaching this transition from a position of strength, and you will hear that reflected in the progress we are sharing today.
Frequently Asked Questions About TVTX
Did TVTX beat earnings estimates last quarter?
No. Travere Therapeutics reported EPS of -$0.55 for the quarter ended Sep 30, 2026, below the -$0.25 estimate by 120.00%.
What EPS do analysts expect from TVTX next quarter?
The consensus EPS estimate for Travere Therapeutics for the quarter ending Dec 31, 2026 is $0.48 from 16 analysts, with estimates from $0.09 to $0.99.
How often does TVTX beat earnings estimates?
Travere Therapeutics beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of +125.44%.
TVTX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts